Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

Gastroenteritis Clinical Trial

Official title:

Phase 2, Single-arm, Open-label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular HIL-214 Norovirus Vaccine in Adults Aged 18 to 49 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05972733
• Other study ID #: NOR-215
• Status: Completed
• Phase: Phase 2
• Start date: August 2, 2023
• Est. completion date: November 10, 2023

Study information

• Verified date: January 2024
• Source: HilleVax
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to obtain serum for proficiency testing to confirm assay validity is maintained following the dosing of adults with a pediatric dose of HIL-214.

Description:

This single-arm trial serves to obtain serum for proficiency testing to confirm assay validity is maintained. Exploratory aspects of this trial include evaluating additional assays used for the assessment of immune responses to HIL-214 in peripheral-blood samples. Given the large volume of blood required, the pediatric dose will be tested in healthy adults. The main scientific rationale for the trial is to identify immune assays that can assess the generation of serum antibodies or cell-mediated immunity (CMI) specific to norovirus strains not represented in the HIL-214 vaccine (i.e. cross-reactivity).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: November 10, 2023
• Est. primary completion date: August 14, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Male or female subjects aged 18 to 49 years, inclusive.

• Individuals who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.

• The individual signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to regulatory requirements.

• Individuals willing and able to comply with trial procedures and are available for the duration of follow-up.

Exclusion Criteria:

• Females who are pregnant or breastfeeding.

• Gastroenteritis within 14 days before planned dosing (can warrant delay of trial vaccine administration).

• Known hypersensitivity or allergy to any of the HIL-214 components (including excipients).

• Known or suspected impairment/alteration of immune function, including history of any autoimmune disease or neuro-inflammatory disease.

• Any serious chronic or progressive disease (including hepatitis B or C).

• Previous exposure to an experimental norovirus vaccine.

• Subject or subject's first-degree relatives are involved in the trial conduct.

Related Conditions & MeSH terms

• Gastroenteritis

Intervention

Biological:
• HIL-214
HIL-214

Locations

Country	Name	City	State
United States	Pennisula Research Associates	Rolling Hills Estates	California
United States	Clinical Research Atlanta	Stockbridge	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
HilleVax

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Immunogenicity for Panel Formation	For the 80 subjects enrolled in the trial, the serum samples that will be collected will be used to produce a proficient assay panel based on immunogenicity results of the initial testing. This panel that is formed will be used for further analysis in other clinical trials.	6 months